Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Uridine-cytidine kinase-like 1 (UCKL1)
- Target
- UCKL1
- Molecular classification
- Enzyme, Kinase
01
Overview
Uridine-cytidine kinase-like 1 (UCKL1) is an enzyme that phosphorylates uridine and cytidine in the pyrimidine salvage pathway, forming uridine monophosphate. UCKL1 plays a critical role in cellular nucleotide metabolism and is upregulated in several cancers, where it supports cell survival and resistance to apoptosis. It interacts with both viral (Epstein-Barr nuclear antigen 3) and immunological (natural killer lytic-associated molecule) partners, and its degradation is associated with increased apoptosis in tumor cells. Its overexpression is observed in hepatocellular carcinoma and may be clinically relevant in oncology as a putative oncoprotein and therapeutic target, although its utility as a biomarker alone is limited.
- Other names
- URKL1UCK1LUCK1-LIKEF538FLJ20517uridine-cytidine kinase 1 like 1
02
Mechanism of action
Modulation of pyrimidine salvage pathway via kinase activity; drugs may potentially target enzymatic action or impact cell viability through altering nucleotide pools
03
Biological functions
Pyrimidine nucleotide salvagePhosphorylation of uridine and cytidineNucleotide metabolismContribution to cell proliferationPromotion of tumor cell survivalResistance to apoptosis
04
Disease associations
Cancer (including lung carcinoma and hepatocellular carcinoma)Orotic aciduriaPotential oncology target (oncoprotein)
05
Safety considerations
No specific drug-related safety concerns reportedpotential challenges could include effects on normal proliferating cells due to role in nucleotide salvageunknown off-target impacts if inhibited systemically
06
Interacting drugs
Uracil
3 more in the full profile.
07
Biomarkers
Elevated UCKL1 expression in tumor tissues (especially hepatocellular carcinoma in hepatitis C–positive patients)not a strong standalone prognostic marker but relevant in combination with other markers such as IL28B polymorphisms
Beyond the preview
Go deeper on Uridine-cytidine kinase-like 1 (UCKL1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Uridine-cytidine kinase-like 1 (UCKL1).